Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin

E-ISSN： 1873-5576|16|4|288-304

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.16, Iss.4, 2016-04, pp. : 288-304

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chronic rapamycin treatment exacerbates metabolism and does not down-regulate mTORC2/Akt signaling in diabetic mice induced by high-fat diet and streptozotocin

By WangYan HeZhi LiXianhui ChenWenwei LuJiewen ChenXiangping CaoLiang

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 9, 2015-09 ,pp. : 604-609

Govi-Verlag

Access to resources Recommend Favorite

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy

By Vaddi Kris Luchi Monica

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 961-973

Informa Healthcare

Access to resources Recommend Favorite

Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin

Current Drug Targets, Vol. 12, Iss. 8, 2011-07 ,pp. : 1223-1231

Bentham Science Publishers

Access to resources Recommend Favorite

New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPAR&ggr; Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy

Current Cancer Drug Targets, Vol. 5, Iss. 6, 2005-09 ,pp. : 393-419

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 237-249

Bentham Science Publishers

Access to resources Recommend Favorite